Over the past few years, Russia has seen steady growth in sales of hormonal contraceptives (EphMRA classification group G03A). The exception was 2023, when sales of such products declined by 1% compared to 2022, due to frenzied demand during the comparison period. According to the database “Audit of retail sales of medicines in Russia (total sell-out)”, 8.9 million packs of hormonal contraceptives were sold on the retail market (including online channels) in January-May 2025, worth 13.9 billion rubles (at retail prices, including VAT). The dynamics relative to the same period in 2024 amounted to 7.3% in real terms and about 12.8% in ruble terms. The growth rate in packages in the current year was significantly higher than in 2024, when the real growth rate was 4.1%. In total, over 20.9 million packages of such products were purchased at retail in 2024, amounting to more than 31.5 billion rubles.

The regional structure of consumption and demand dynamics for hormonal contraceptives is extremely uneven. We recorded the highest natural sales growth rates in the Chechen Republic (+23% in packs), Tambov (+20.1%) and Irkutsk regions (+18.8%). A decline in demand was recorded in the Republic of Ingushetia (-8.1%), with a pronounced negative trend observed in the Republic of Sakha (Yakutia) and Magadan Region (both regions -3.6%), but overall, sales declined in only 12 Russian regions.

Oral contraceptives dominate the group, accounting for more than 85% of the actual consumption of all hormonal contraceptives analyzed. Sales of oral contraceptives increased by 11% in rubles and 5% in packages over the year. At the end of the first five months of 2025, the retail segment of the hormonal contraception market included 44 brands, comprising more than 90 SKUs. At the same time, only 11 corporations represent their products in the analyzed group, among which only two foreign companies, Bayer Healthcare (55% share) and Gedeon Richter (34%), account for about 89% of the ruble market. The products of these companies make up the top 10 brands in terms of sales volume. The Yaz brand from Bayer Healthcare retains its market leadership among systemic hormonal contraceptives. The brand accounts for 17.6% of all sales in the group, with ruble sales of the medicine increasing by 7% over the year. The second and third positions in the ranking are also occupied by Bayer Healthcare products: Qlaira (14% share) and Yarina (11.4%).

All TOP-10 participants showed positive sales dynamics in the analyzed period, with the highest growth rates recorded for Qlaira (+21%). Outside the top 10, the highest growth was recorded by the PlaniJens cipro brand from the domestic company Pharmasyntez, with consumption in packages tripling over the year and total cash expenditure on it increasing 3.6 times.

Table TOP-10 brands of systemic hormonal contraceptives (group G03A – according to the EphMRA classifier), by cash sales volume on the Russian retail pharmaceutical market in January-May 2025